Sentiment Survey
|
|
|
|
|
|
|
|
|
|
|
|
Investment Grade:
|
|
Comments(0)
|
(0)
|
(0)
|
Ranking History
Headlines
- Emerging Biotech & Pharma Index: 36 More Cos.
Nov 24, 2008 01:40 AM
- Updated FDA Calendar Of 73 Decision Dates
Nov 22, 2008 12:57 PM
- GSK Boosts Theravance, Near-Term
Jun 26, 2008 10:32 AM
- New England Journal of Medicine Publishes Results From a RELISTOR Phase 3 Clinical Study
May 29, 2008 08:59 AM
- New England Journal of Medicine Publishes Results From a RELISTOR Phase 3 Clinical Study
May 29, 2008 08:59 AM
- Analyst Comments: MCG Capital, TELUS, Smith International, Theravance, Omnicom, China Mobile
Apr 23, 2008 10:17 AM
- Theravance 1Q Loss Narrows, Sees $5.8 Million Charge On Work Force Cut
Apr 21, 2008 04:44 PM
- Media Digest for 4/14
Apr 14, 2008 10:33 AM
- Analyst Comments: XL Capital, Sinopec, SCOR Group, Cleveland-Cliff, Dell, Millennium Pharma, Theravance
Apr 11, 2008 01:40 AM
- Theravance: FDA Accepts Co's Response For NDA Telavancin
Mar 05, 2008 04:51 PM
- GSK and Theravance Announce Positive Phase 2b Results for LABA, '444 in the Horizon Asthma Development Programme
Dec 02, 2008 08:01 AM
- Theravance Announces New Employment Inducement Awards
Dec 01, 2008 06:30 PM
- Theravance Reports Favorable Outcome of FDA Advisory Committee Meeting on Telavancin for the Treatment of Complicated Skin and Skin Structure Infections
Nov 19, 2008 02:41 PM
- Trading in Theravance Common Stock Halted
Nov 19, 2008 07:05 AM
- Theravance Announces Posting of Briefing Documents for FDA Anti-Infective Drugs Advisory Committee Meeting on Telavancin
Nov 17, 2008 09:23 AM
- Theravance to Present at the Credit Suisse Phoenix Healthcare Conference
Nov 04, 2008 04:05 PM
- Theravance Announces New Employment Inducement Awards
Nov 03, 2008 06:15 PM
- Theravance Reports Third Quarter 2008 Financial Results
Oct 23, 2008 04:05 PM
- Telavancin Data to Be Presented at Upcoming Scientific Conferences
Oct 16, 2008 04:05 PM
- Theravance Announces FDA Advisory Committee to Review Telavancin for the Treatment of Complicated Skin and Skin Structure Infections
Oct 14, 2008 11:59 AM
Analyst Ratings
|
|
Share Performance
|
Period
|
THRX
|
Compare to S&P
|
| YTD |
-68.46 %
|
-0.01 %
|
| 4 Weeks |
-8.21 %
|
8.67 %
|
| 12 Weeks |
-54.44 %
|
-29.24 %
|
|
Financial Ratios
Earnings Performance
|
EPS Growth in Last Quarter: 5.56 %
|
|
EPS Growth in Last Year: 35.85 %
|
|
Sales Growth in Last Quarter: 8.97 %
|
|
Sales Growth in Last Quarter: 5.82 %
|
|
|
